Passage Bio Announces 1-for-20 Reverse Stock Split
MWN-AI** Summary
On July 10, 2025, Passage Bio, Inc., a Philadelphia-based clinical-stage genetic medicines company, announced a significant corporate action: a 1-for-20 reverse stock split of its common stock, effective at 12:01 a.m. Eastern time on July 14, 2025. This decision, sanctioned by the company’s Board of Directors and approved by shareholders at the annual meeting on May 28, 2025, is aimed at regaining compliance with Nasdaq’s minimum bid price requirement of $1.00 per share.
Following the reverse split, Passage Bio's total outstanding shares will decrease from approximately 62.4 million to roughly 3.1 million. Although the number of shares will be reduced, it will not affect the total ownership interests of existing shareholders, apart from potential fractional shares, which will be rounded up to the nearest whole share. The trading of the common stock will continue under the ticker symbol “PASG,” with a new CUSIP number (702712 209) assigned for post-split shares.
The company’s transfer agent, Computershare Trust Company, N.A., will facilitate the exchange process for stockholders, ensuring a seamless transition without requiring action from registered shareholders or those holding shares in brokerage accounts, commonly referred to as "street name."
Passage Bio focuses on developing innovative therapies for neurodegenerative diseases and has a lead product candidate, PBFT02, targeting frontotemporal dementia. The company emphasizes its commitment to improving patient outcomes through cutting-edge genetic medicine approaches.
This restructuring reflects Passage Bio's efforts to stabilize its stock price and maintain its listing on the Nasdaq Capital Market, amidst regulatory challenges and market volatility.
MWN-AI** Analysis
Passage Bio, Inc.'s announcement of a 1-for-20 reverse stock split is a significant step for the company as it aims to comply with Nasdaq's minimum bid price requirement of $1.00 per share. While such splits are often viewed with skepticism by investors, there are underlying reasons and potential implications for stakeholders that merit consideration.
First and foremost, the reverse split is indicative of the company's necessity to stabilize its stock price and strengthen its market standing. The reduction in outstanding shares from approximately 62.4 million to about 3.1 million is expected to boost the per-share price, making it appear more attractive to institutional investors who may have policies against purchasing “penny stocks”.
Investors should note that while a reverse stock split does not alter the company’s overall market capitalization, it often leads to increased volatility in the short term. Historically, reverse splits can result in mixed market reactions, where initial price surges may be followed by declines as the underlying fears that led to the split surface. For potential investors, it’s crucial to assess Passage Bio's fundamentals, particularly its lead product candidate, PBFT02. This treatment for neurodegenerative diseases could be a game changer if the clinical trials are successful.
With a focus on innovative therapies, Passage Bio appears to be on the cusp of either potential breakthrough or further struggle, depending on its clinical outcomes and market conditions. As the reverse stock split approaches, existing shareholders may want to re-evaluate their positions. New investors should consider entering with caution, balancing the possibilities of future growth against the inherent risks associated with biotechnology and the market’s response to this corporate action.
In conclusion, while the reverse stock split may provide Passage Bio with a much-needed financial cushion, due diligence will be critical for all investors navigating this post-split landscape. Monitoring upcoming clinical trial results and market reactions will be essential in determining the stock’s viability moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors (“ Board ”) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025. Passage Bio’s common stock will begin trading on a post-reverse stock split basis on July 14, 2025, under the Company’s existing trading symbol “PASG” with a new CUSIP number of 702712 209. The reverse stock split is intended to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share.
The reverse stock split was approved by Passage Bio’s stockholders, at the Company’s 2025 annual meeting of stockholders held on May 28, 2025, to be effected at the Board’s discretion within approved parameters. The reverse stock split reduces the number of shares of the Company’s outstanding common stock from approximately 62,405,898 shares to approximately 3,120,295. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Passage Bio’s common stock underlying the Company’s outstanding equity awards for common stock, as well as the number of shares issuable under the Company’s equity incentive and inducement plans, and employee stock purchase plan. There will be no change to the number of authorized shares or to the par value per share.
Information for Passage Bio’s Stockholders
Passage Bio’s transfer agent, Computershare Trust Company, N.A., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of Passage Bio’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split. None of Passage Bio’s common stock is held in certificate form. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares will receive the number of shares of common stock as rounded up to the nearest whole share. The reverse stock split will affect all of the Company’s stockholders uniformly and would not affect any stockholder’s percentage ownership interests, except to the extent that the reverse stock split results in such stockholder owning a fractional share.
About Passage Bio, Inc.
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com .
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to, Passage Bio’s future stock price, the effects of the reverse stock split on stockholders, compliance with Nasdaq listing standards and Passage Bio’s ability to remain listed on the Nasdaq Capital Market. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Passage Bio is contained in the section captioned "Risk Factors" in documents the Company files from time to time with the Securities and Exchange Commission (“ SEC ”) and other reports as filed with the SEC. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and regulatory approvals. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Investor Contact:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
FAQ**
What are the long-term implications for **Passage Bio Inc. (PASG)** following the reverse stock split, particularly regarding its stock price and investor confidence?
How might the outcomes of **Passage Bio Inc. PASG**’s lead product candidate, PBFT0influence the company's stock performance post-reverse split?
What strategies does **Passage Bio Inc. (PASG)** have in place to ensure compliance with Nasdaq's listing standards beyond the reverse stock split?
Given the reverse stock split, how will **Passage Bio Inc. PASG** address potential concerns from investors regarding equity dilution or future fundraising efforts?
**MWN-AI FAQ is based on asking OpenAI questions about Passage Bio Inc. (NASDAQ: PASG).
NASDAQ: PASG
PASG Trading
3.35% G/L:
$8.185 Last:
4,790 Volume:
$8.185 Open:
